Meta-analysis of serum C-reactive protein and cartilage oligomeric matrix protein levels as biomarkers for clinical knee osteoarthritis

Junfeng Zhang

Abstract

Background: The roles of C-reactive protein (CRP) and cartilage oligomeric matrix protein (COMP) in knee osteoarthritis (KOA) remain controversial, thus the present study is aimed to explore the relationships between CRP, COMP, and the incidence/progression of KOA.

Methods: A systematic search was conducted on PubMed and Embase until September, 2016 for all the relevant studies. The pooled mean difference (MD) with its 95% confidence interval (95% CI) based on fixed effects model or random effects model was calculated to assess the potential role of CRP and COMP in the incidence or progression of KOA. Heterogeneity was evaluated by Cochran’s Q and I² tests. When \( P < 0.05 \) or \( I^2 > 50\% \), a random effects model was chosen, otherwise, a fixed effects model was used. Moreover, the role of CRP in different degrees of pain was also analyzed. Sensitivity analysis was performed to evaluate the strength of the meta-analysis.

Results: Fourteen studies were enrolled in the meta-analysis. No difference was found between baseline CRP and CRP levels in the last follow-up period of KOA (MD = −0.09, 95% CI: -0.30, 0.13). Pooled data showed higher CRP concentration in patients with incident KOA when compared with controls (MD = 0.33, 95% CI: 0.04, 0.63). Moreover, higher serum COMP levels were found in patients with incident KOA (MD = 1.69, 95% CI: 0.61, 2.76) Additionally, significant higher CRP concentration was observed in KOA patients with highest degree of pain (MD = 1.60, 95% CI: 0.52, 2.67).

Conclusion: CRP and COMP serum levels were both associated with the incidence of KOA. Patients with a higher CRP and COMP concentration might have an increased probability of developing KOA. However, higher CRP serum levels was not related with KOA progression. Furthermore, KOA patients with more pain had higher CRP concentrations.

Keywords: C-reactive protein, Knee osteoarthritis, Pain, Meta-analysis

Background

Osteoarthritis (OA), the most common type of arthritis, is characterized by joint space deterioration, pain, and loss of motion. Epidemiology studies have observed high prevalence of OA both in developed countries and developing countries. For example, the overall prevalence of knee OA was found to be 28.7% in India [1], the prevalence was highest (13.7%) in subjects living in the South-West region in China [2], and OA affected nearly 27 million Americans [3]. Additionally, the prevalence and incidence of the disease continue to increase. OA can become both a financial and health burden to patients and can affect their quality of life. Therefore, it is urgent to find an effective way to diagnosis and prevent the incidence or progression of OA in the early stage of disease.

Inflammation plays an important role in the pathogenesis of OA, although the specific correlations between biomarkers of inflammation and knee osteoarthritis (KOA) remain controversial. C-reactive protein (CRP) is a pentameric protein found in blood plasma associated with
inflammation, infection, and injury. Studies demonstrated that CRP was correlated with complications, such as hypertension, cardiovascular disease, and diabetes [4, 5]. Studies have suggested that KOA was significantly related with CRP concentration [6, 7]. Other studies suggested that there were significant association between CRP concentration and KOA incidence [8–10]. Cartilage oligomeric matrix protein (COMP) is a 535-kDa non-collagen protein which has strong relation with the incidence of KOA. Some evidence has demonstrated that COMP serum levels in OA was different from healthy controls.

Because of these conflicting reports, the purpose of this study was to evaluate the association between CRP concentration, COMP serum levels and the incidence/progression of KOA. The relationship between CRP concentration and pain in KOA patients was also assessed.

Methods

Search strategy and study selection

A systematic search was performed on PubMed and Embase from database inception through September 2016. The following search terms were used: “osteoarthritis”, “knee osteoarthritis”, “C-reactive protein”, “CRP”, “cartilage oligomeric matrix protein”, “COMP”. Search terms were combined with OR and AND. All the reference list of retrieved studies and any additional publication were also searched and screened. The study was conducted based on the PRISMA guidelines [11].

Inclusion criteria

The included studies were in line with the following criteria: 1) subjects had clinical KOA; 2) investigated the association between KOA incidence and progression and the concentration of CRP or COMP serum levels; 3) parameter of CRP or COMP could be extracted or calculated; 4) published in English. We excluded studies in which KOA patients were formerly treated by medication. In addition, repeated studies, reviews, comments, and letters were also excluded.

Data extraction and quality assessment

Data were extracted by two independent researchers following pre-designed form. The quality assessment was performed independently by two reviewers, and disagreement would be solved by the third reviewer.

Baseline characteristics of the eligible studies included first author, publication year, patients’ demographic, study design, research area, the concentration of CRP and COMP serum levels, and the number of the number of KOA and control patients. The quality of the studies was assessed by Newcastle-Ottawa Scale (NOS) [12]. In brief, NOS contains 8 items, categorizes into three groups, and with a total score of 9 stars. Each eligible study was graded according to this tool. In the current study, a cohort study with a follow-up rate > 75% was assigned one star. If NOS score of the study reached more than 5, it was considered as high quality literature, and was suitable for the meta-analysis.

Statistical analysis

We extracted mean difference(MD) and standard deviation(SD) of CRP and COMP levels at baseline and at the end of the follow-up period of study subjects and controls. Heterogeneity among the included studies was calculated by Cochrane’s Q-test and I² test [13]. P < 0.05 or I² > 50% was defined as significant heterogeneity between individual studies. Then, the random effects model was selected for pooling MD and SD of CRP and COMP levels to assess the association between CRP and COMP concentration and KOA incidence and progression. When P > 0.05 or I² < 50%, a fixed effect model was chosen to pool MD and SD of CRP and COMP levels. Sensitivity analyses were performed by changing one study at a time, to see what effect this produces on the outcome. All statistical analysis was performed by Cochrane Collaboration Review Manager (version 5.3). We considered P < 0.05 as statistically significant.

Results

Search results and study selection

As shown in Fig. 1, the initial search yielded a total of 982 articles. 537 remained after removing the duplicated articles. 392 studies were further excluded because they did not investigate the relationship between CRP or COMP concentration and the incidence/progression of KOA. A total of 145 articles were under full-text review, of which 131 studies were excluded. Among the 131 articles, 91 articles were reviews, comments or case reports, 25 studies did not provide sufficient data, 14 studies were not about KOA incidence or progression, and 1 duplicate population [9, 14]. Eventually, 14 articles were included in the meta-analysis [6, 7, 14–25]. All relevant baseline characteristics of the enrolled studies were summarized in Table 1. In general, nine studies were designed as case control, and five were designed as cohort
studies. Four studies were conducted in Asia, seven were performed in Europe, one was in Australia, and two were in the USA. Study sizes ranged from 15 to 5171 patients, and the follow-up period ranged from 2 weeks to 12.4 years. Furthermore, all the included studies were scored more than 5 stars based on the NOS criteria, suggesting all enrolled studies were suitable for meta-analysis.

**Meta-analysis of the association between KOA progression and CRP levels**

As shown in Fig. 2a, 5 studies including 836 KOA patients at baseline and 748 patients at the end of the follow-up period evaluated the association between KOA progression and CRP levels [6, 16–18, 21]. Significant heterogeneity was observed among the five studies ($P < 0.00001, I^2 = 93\%$). Therefore, a random effects model was used to pool data. No difference was found between baseline CRP and CRP levels at the last follow-up period in KOA patients (MD = 0.09, 95%CI: -0.30, 0.13). Because there was significant heterogeneity among the studies, sensitivity analysis was performed, and no discrepancy results were observed when we omitted one study at a time (Table 2).

**Meta-analysis of the association between KOA incidence and CRP levels**

Four studies including 557 KOA patients and 7417 controls were enrolled in the meta-analysis to assess the

---

**Table 1** Baseline characteristics of enrolled studies

| Study          | Design          | Number | Age (years) | Follow-up area | Area |
|----------------|-----------------|--------|-------------|----------------|------|
| Fernandes, 2007| Case control    | KOA:75 Control: 40 | KOA:56.6 ± 7.6; Control: 53.8 ± 8.5 | NA | Brazil |
| Senolt, 2005   | Case control    | KOA:38 Control: 38 | KOA:64.1 ± 10.1; Control: 58.3 ± 9.1 | NA | USA |
| Wakitani, 2007 | Case control    | KOA:31 Control: 24 | KOA:20–80; Control: 23–52 | NA | Japan |
| Li, 2012       | Case control    | KOA:115 Control: 35 | KOA:55 ± 13.2; Control:53 ± 12.33 | 2–3 years | China |
| Engstrom, 2009 | population-based cohort | 5171 | 57.5 ± 5.9 | 12.4 years | Sweden |
| Zhang, 2015    | Case control    | Control: 20 KOA: 20 | Control:56.3 ± 7.9; KOA: 59.2 ± 8.3 | NA | China |
| Sowers, 2002   | cohort          | 1025 | 42.9 ± 0.1 | 2.5 years | USA |
| Kerkhof, 2010  | Case control    | KOA: 210; Control: 1360 | 755 years | NA | Netherlands |
| Haghighian, 2014| Case control    | 23 | 58.27 ± 7.84 | 2 months | Iran |
| Ramirez, 2014  | cohort          | 186 | 61 ± 7.3 | 2 years | Netherlands |
| Nielsen, 2014  | Case control    | 281 | 40–80 | NA | Denmark |
| Scorei, 2011   | Case control    | 15 | 67.6 (5.5) | 2 weeks | Romania |
| Stannus, 2012  | cohort study    | KOA:35; Control:114 | KOA:63.2 ± 6.9; Control: 61.5 ± 6.7 | 5 years | Australia |
| Hosnjieh, 2016 | population-based prospective cohort | 1335 | 65.2 (8.43) | 5-year | Netherlands |

**KOA** knee osteoarthritis

---

**Fig. 2** Pooled effect size of the relationship between C-reactive protein (CRP) concentration and knee osteoarthritis (KOA). a the association between CRP concentration and KOA progression; b the association between CRP concentration and KOA incidence
A random effects model was selected due to significant heterogeneity among studies ($P < 0.00001$, $I^2 = 96\%$). The pooled MD with its 95% CI suggested that CRP concentration was somewhat higher in KOA patients when compared with healthy controls (MD = 0.33, 95% CI: 0.04, 0.63). High heterogeneity also existed in this subgroup. Therefore, sensitivity analysis was conducted by deducting one study at a time. When we removed the study by Engstrom et al., Hosnijeh et al., and Zhang et al., pooled data suggested no significant difference in CRP concentration between KOA patients and healthy controls (Table 2).

### Table 2 Sensitivity analysis for the meta-analysis

| Outcomes               | No. of studies | MD(95% CI)       | Heterogeneity test |
|------------------------|----------------|------------------|--------------------|
|                       |                |                  | $P$                | $I^2$ (%) |
| KOA progress with CRP  | All studies    | 0.09 [-0.30, 0.13] | < 0.00001          | 93.0     |
|                        | Haghighian, 2014 | 0.07 [-0.04, 0.18] | 0.02               | 70.0     |
|                        | Hosnijeh, 2016  | -0.15 [-0.77, 0.47] | < 0.00001          | 94.0     |
|                        | Ramirez, 2014   | -0.07 [-0.29, 0.16] | < 0.00001          | 94.0     |
|                        | Scorei, 2011    | -0.15 [-0.78, 0.49] | < 0.00001          | 94.0     |
|                        | Zhang, 2015     | -0.20 [-0.42, 0.02] | < 0.00001          | 93.0     |
| KOA incidence with CRP | All studies     | 0.33 [0.04, 0.63]  | < 0.00001          | 96.0     |
|                        | Engstrom, 2009  | 0.39 [-0.08, 0.86]  | < 0.00001          | 97.0     |
|                        | Hosnijeh, 2016  | 0.45 [-0.05, 0.95]  | < 0.00001          | 97.0     |
|                        | Kerkhof, 2010   | 0.46 [0.06, 0.86]   | < 0.00001          | 97.0     |
|                        | Zhang, 2015     | 0.09 [-0.03, 0.21]  | 0.01               | 76.0     |
| KOA pain with CRP      | All studies     | 1.60 [0.52, 2.67]   | 0.001              | 85.0     |
|                        | Nielsen, 2014   | 1.69 [-0.02, 3.40]  | 0.03               | 78.0     |
|                        | Sowers, 2002    | 1.13 [0.44, 1.82]   | 0.49               | 0.0      |
|                        | Stannus, 2012   | 1.88 [0.76, 3.00]   | 0.003              | 89.0     |

KOA knee osteoarthritis, CRP C-reactive protein

Sensitivity analysis was performed to evaluate the strength of this conclusion, and no inconsistent results were found when we omitted each study (Table 2).

### Meta-analysis of the association between CRP levels and pain in KOA patients

As shown in Fig. 4, three studies estimated the correlation between CRP levels and pain in KOA patients [15, 19, 20]. A total of 2291 patients were included, among them 1112 patients reported knee pain at baseline assessment, and 1179 patients without knee pain were set as controls. Higher mean concentrations of CRP were found in patients who self-reported the highest level of knee pain (MD = 1.60, 95% CI: 0.52, 2.67). When we removed the study by Nielsen et al. in the sensitivity analysis, the significant difference between groups disappeared.

### Discussion

For inflammatory diseases, C-reactive protein (CRP) concentration is recognized as the most common laboratory marker; several clinical studies put forward that CRP concentration is associated with the progression of osteoarthritis. In this study, we conducted a meta-analysis to investigate the association between serum CRP levels and osteoarthritis incidence and pain.

The association between CRP levels and knee osteoarthritis (KOA) incidence and pain was investigated. The pooled MD for CRP concentration in KOA patients was 0.33 (95% CI: 0.04, 0.63), indicating a higher concentration in KOA patients compared to healthy controls. However, the heterogeneity was high ($I^2 = 96\%$). Sensitivity analysis showed that the conclusion was robust when the study by Engstrom et al., Hosnijeh et al., and Zhang et al. were excluded.

CRP concentration was also found to be associated with pain in KOA patients. The pooled MD for pain was 1.60 (95% CI: 0.52, 2.67), suggesting a higher pain level in KOA patients with higher CRP levels. Sensitivity analysis revealed that the conclusion was consistent when the study by Nielsen et al. was excluded.

These findings support the role of CRP as a biomarker for osteoarthritis, and further studies are needed to validate these findings and explore the clinical implications of CRP in the management of osteoarthritis.
concentration was elevated in patients with KOA [26]. Additionally, COMP serum levels are also considered as a potential biomarker for the diagnosis of KOA. The present meta-analysis demonstrated that higher CRP concentration was associated with higher KOA incidence, however, CRP levels were not related to the progression of KOA. Moreover, CRP concentration was higher in KOA patients with higher degrees of knee pain. Higher serum COMP levels in patients with incident KOA were also observed. Thus, both CRP and COMP could serve as useful biomarkers of KOA.

The outcome of our study suggests that CRP as a biomarker plays a positive role in the diagnosis and prognosis of KOA. This finding is consistent with a previous study [27]. However, in sensitivity analysis, when removing the study by Engstrom et al. [6], Hosnijeh et al. [17], and Zhang et al. [21], the significant difference of CRP levels between KOA patients and control group diminished. Thus, further study enrolling larger sample size and balancing confounding factors such as patient’s backgrounds is needed. Although significantly higher COMP serum levels was observed in incident KOA, no stratified analysis based on severity of KOA was performed due to limited enrolled studies. Further investigation is required to determine if this marker can be utilized to assess the incidence OA. Given that both CRP and COMP levels were higher in patients with KOA, the two factors could be used in combination for the prognosis of KOA.

Significant heterogeneity existed in our study. Although we conducted sensitivity analysis to assess the strength of the meta-analysis using one-at-a-time method, heterogeneity did not reduce. In patients with early KOA, many factors could affect the concentration of CRP, such as life habit and the background of KOA. For example, a previous study indicated that cigarette smoking was positively associated with serum CRP levels [28]. In addition, experimental data suggested both dietary and serum Mg were inversely related with serum CRP in early radiographic KOA patients [29]. Moreover, serum CRP was associated with knee bone marrow lesions scores [30]. Thus, future study stratified by living habit and background of patients should be performed to verify the present conclusion.

There are some limitations should be noted in the meta-analysis. First, the number of enrolled subjects was small, which limited the subgroup analysis stratified by smoking status, and other confounding factors such as hyperlipidemia. Second, we did not restrict the timing of biomarker assessment, and exercise status of the patients, also the follow-up period ranged from 2 weeks to 12.4 years, which might be one of the reasons causing significant heterogeneity among individual studies. Third, a number of studies did not provide calculated data. Moreover, other chronic diseases might influence the CRP levels in patients, and we did not eliminate the effect of those factors. Our study was designed to evaluate the relationship between biomarkers and KOA. The association between CRP and other OA types, such as hand, hip, and spine OA was not considered.

### Conclusion

The present meta-analysis indicated that both CRP and COMP could serve as biomarkers for KOA. Higher CRP and COMP serum levels might be associated with a higher incidence of KOA. However, higher CRP concentration was not associated with the progression of KOA. Further study is required verify the actual relationship between CRP and KOA incidence.

### Abbreviations

- CI: Confidence interval
- COMP: Cartilage oligomeric matrix protein
- CRP: C-reactive protein
- KOA: Knee osteoarthritis
- MD: Mean difference
- OA: Osteoarthritis

### Acknowledgements

I would like to thank Dr. Liu Shaolong for his valuable guidance in every stage of the writing of this thesis. Also, I shall extend my thanks to Haiyuan Dong from General Office of Shanxi Medical Journal and Qianqian He from Shanxi Medical University for their kind help in the data extraction and quality assessment processes.

### Funding

This study was sponsored by the National Natural Science Foundation of China (No. 81573245); Shanxi provincial health and Family Planning Commission projects (No. 2014169).

### Availability of data and materials

All data generated or analysed during this study are included in this published article.

### Authors’ contributions

Only ZJF conceived this study, participated in the experiments and finally wrote the paper. ZJF approved the final manuscript.

### Ethics approval and consent to participate

Not applicable

### Consent for publication

Not applicable
Competition interests
The author declares that he/she has no competing interests.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 9 September 2017 Accepted: 10 January 2018
Published online: 19 January 2018

References
1. Pal CP, Singh P, Chaturvedi S, Pruthi KK, Vij A. Epidemiology of knee osteoarthritis in India and related factors. Indian J Orthop. 2016;50:18–22.

2. Tang X, Wang S, Zhan S, Niu J, Tao K, Zhang Y, Lin J. The prevalence of symptomatic knee osteoarthritis in China: results from the China health and retirement longitudinal study. Arthritis Rheumatol. 2016;68:468–53.

3. Isa SN, Sharma L. Epidemiology of osteoarthritis: an update. Curr Rheumatol Rep. 2006;8:7–15.

4. Abili H, Meinders A. C-reactive protein: history and revival. Eur J Intern Med. 2002;13:412.

5. Dalton RR, Hoffman WH, Passmore GG, Martin SL. Plasma C-Reactive protein levels in severe diabetic ketoacidosis. Ann Clin Lab Sci. 2003;33:435–42.

6. Engstrom G, Gerhardsson de Verdier M, Rolfos J, Nilsson PM, Lohmander LS. C-reactive protein, metabolic syndrome and incidence of severe hip and knee osteoarthritis. A population-based cohort study. Osteoarthr Cartil. 2005;13:168–73.

7. Kerkhof HJ, Biema-Zeinstra SM, Castano-Betancourt MC, de Maat MP, Hofman A, Pols HA, Ravendeaire F, Witteman JC, Uitlinderen AG, van Meurs JB. Serum C reactive protein levels and genetic variation in the CRP gene are not associated with the prevalence, incidence or progression of osteoarthritis independent of body mass index. Ann Rheum Dis. 2010;69:1976–82.

8. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis. 2001;60:19–26.

9. Sanchez-Ramirez DC, van der Leeden M, van der Esch M, Roorda LD, Verschueren S, van Dieren J, Lems WF, Dekker J. Increased knee muscle strength is associated with decreased activity limitations in established knee osteoarthritis: two-year follow-up study in the Amsterdam osteoarthritis cohort. J Rehabil Med. 2015;47:647–54.

10. Conrozier T, Chappuis-Cellier C, Richard M, Mathieu P, Richard S, Vignon E. Serum C reactive protein levels by immunonephelometry in patients with rapidly destructive hip osteoarthritis. Rev Rhum Engl Ed. 1998;65:759–65.

11. Moheb D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–41.

12. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:45.

13. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820–6.

14. Sanchez-Ramirez DC, van der Leeden M, van der Esch M, Roorda LD, Verschueren S, van Dieren JH, Dekker J, Lems WF. Elevated C-reactive protein is associated with lower increase in knee muscle strength in patients with knee osteoarthritis: a 2-year follow-up study in the Amsterdam osteoarthritis (AMS-OA) cohort. Arthritis Res Ther. 2014;16:R123.

15. Arendt-Nielsen L, Eskehave TN, Esgaard LL, Petersen KK, Graven-Nielsen T, Hoek HC, Simonsen O, Siebuhr AS, Karsdal M, Bay-Jensen AC. Association between experimental pain biomarkers and serologic markers in patients with knee osteoarthritis. Acta Med. 2015;53:207–13.

16. Khadem Haghighian M, Alipoor B, Malek Mahdavi A, Eftekhari Sadat B, Aghadi Jafarabadi M, Moghadam A. Effects of sesame seed supplementation on inflammatory markers and oxidative stress biomarkers in patients with knee osteoarthritis. Acta Med Iran. 2015;53:207–13.

17. Saberi Hosnijeh F, Siebuhr AS, Uitlinderen AG, Oei EH, Hofman A, Karsdal MA, Biema-Zeinstra SM, Bay-Jensen AC, van Meurs JB. Association between biomarkers of tissue inflammation and progression of osteoarthritis: evidence from the Rotterdam study cohort. Arthritis Res Ther. 2016;18:81.

18. Scorci R, Mirpur P, Petrisor I, Scorci I. A double-blind, placebo-controlled pilot study to evaluate the effect of calcium fructoborate on systemic inflammation and dyslipidaemia markers for middle-aged people with primary osteoarthritis. Bio Trace Elem Res. 2011;144:253–65.

19. Sowers M, Jannausch M, Stein E, Jamadar D, Hochberg M, Lachance L. C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthr Cartil. 2002;10:595–601.

20. Stannus OP, Jones G, Blizzard L, Cicuttini FM, Ding C. Associations between serum levels of inflammatory markers and change in knee pain over 5 years in older adults: a prospective cohort study. Ann Rheum Dis. 2013;72:353–40.

21. Zhang Q, Li H, Zhang Z, Yang F, Chen J. Serum metabolites as potential biomarkers for diagnosis of knee osteoarthritis. Dis Markers. 2015;2015:684794.

22. Fernandes FA, Pucinelli ML, da Silva NP, Feldman D. Serum cartilage oligomeric matrix protein (COMP) levels in knee osteoarthritis in a Brazilian population: clinical and radiological correlation. Scand J Rheumatol. 2007;36:211–5.

23. Li H, Wang X, Wu ZQ, Zhong JM, Yuan YJ. Serum levels of cartilage oligomeric matrix protein in the diagnosis of knee osteoarthritis. Zhongguo Gu Shang. 2012;25:390–3.

24. Senolt L, Braun M, Olejarova M, Foretova S, Gatterova J, Pavelka K. Increased pentosidine, an advanced glycation end product, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein. Ann Rheum Dis. 2005;64:886–90.

25. Wakitani S, Navata M, Kawaguchi A, Okabe T, Takaoka K, Tsuchiya T, Nakaska R, Masuda H, Miyazaki K. Serum keratan sulfate is a promising marker of early articular cartilage breakdown. Rheumatology (Oxford). 2007;46:1652–6.

26. Takahashi M, Naito K, Abe M, Sawada T, Nagano A. Relationship between radiographic grading of osteoarthritis and the biochemical markers for arthritis in knee osteoarthritis. Arthritis Res Ther. 2004;6:R208–12.

27. Hutter K, Spreng D, Rytz U, Schwaiberl P, Ott-Kruzel F, Schmolke H. Measurements of C-reactive protein in serum and lactate dehydrogenase in serum and synovial fluid of patients with osteoarthritis. Vet J. 2005;169:281–5.

28. Zhang Y, Zeng C, Wei J, Li H, Yang T, Yang Y, Deng ZH, Ding X, Lei G. Associations of cigarette smoking, betel quid chewing and alcohol consumption with high-sensitivity C-reactive protein in early radiographic knee osteoarthritis: a cross-sectional study. BMJ Open. 2016;6:e010763.

29. Li H, Zeng C, Wei J, Yang T, Gao SG, Luo W, Li YS, Xiong YL, Xiao WF, Lei GH. Associations of dietary and serum magnesium with serum high-sensitivity C-reactive protein in early radiographic knee osteoarthritis patients. Mod Rheumatol. 2016;1:6–11.

30. Zhu Z, Jin X, Wang B, Wuika A, Anthony B, Laslett LL, Winzenberg T, Cicuttini F, Jones G, Ding C. Cross-sectional and longitudinal associations between serum levels of high-sensitivity C-reactive protein, knee bone marrow lesions, and knee pain in patients with knee osteoarthritis. Arthritis Care Res (Hoboken). 2016;68:1471–7.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit